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Abstract
Background: Computer-aided, interdisciplinary researches for biomedicine have valuable prospects, as digitalization
of experimental subjects provide opportunities for saving the economic costs of researches, as well as promoting
the acquisition of knowledge. Acute myeloid leukemia (AML) is intensively studied over long periods of time. Till
nowaday, most of the studies primarily focus on the leukemic cells rather than how normal hematopoietic cells are
affected by the leukemic environment. Accordingly, the conventional animal models for AML are mostly myeloablated
as leukemia can be induced with short latency and complete penetrance. Meanwhile, most previous computational
models focus on modeling the leukemic cells but not the multi-tissue leukemic body resided by both leukemic and
normal blood cells. Recently, a non-irradiated AML mouse model has been established; therefore, normal
hematopoietic cells can be investigated during leukemia development. Experiments based on the non-irradiated
animal model have monitored the kinetics of leukemic and (intact) hematopoietic cells in multiple tissues
simultaneously; and thus a systematic computational model for the multi-tissue hematopoiesis under leukemia
has become possible.
Results: In the present work, we adopted the modeling methods in previous works, but aimed to model the
tri-tissue (peripheral blood, spleen and bone marrow) dynamics of hematopoiesis under leukemia. The cell
kinetics generated from the non-irradiated experimental model were used as the reference data for modeling.
All mathematical formulas were systematically enumerated, and model parameters were estimated via
numerical optimization. Multiple validations by additional experimental data were then conducted for the
established computational model. In the results, we illustrated that the important fact of functional depression
of hematopoietic stem/progenitor cells (HSC/HPC) in leukemic bone marrow (BM), which must require
additional experiments to be established, could also be inferred from our computation model that utilized
only the cell kinetics data as the input.
Conclusion: The digitalized AML model established in the present work is effective for reconstructing the
hematopoiesis under leukemia as well as simulating the hematopoietic response to leukemic cell expansion.
Given the validity and efficiency, the model can be of potential utilities in future biomedical studies;
additionally, the modeling method itself can be also applied elsewhere.
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Background
Animal models are constantly built and utilized in medical
researches as manipulable platforms for investigations of
diseases. As self-evident, an appropriate experimental
model is able to represent and reproduce the phenotypes
of disease progression, thus promoting the studies of dis-
ease physiology as well as therapeutics. Experimental
models of mice have been usually applied for researches of
leukemia, especially the acute myeloid leukemia (AML).
However, most of the leukemia models established/utilized
in previous studies rely on protocols of pre-conditioning
the recipients by myeloabative manipulations such as im-
munosuppressive agents, total body irradiation or xeno-
transplantation [1–3]. Although these models are efficient
in leukemia induction with short latency and complete
penetrance [4, 5], obviously, leukemogenesis generally does
not occur in myeloablated or immuno-deficient hosts al-
beit they are robust in terms of disease progression. For
example, in a typically pre-conditioned model, leukemia is
induced by irradiating the host via total body irradiation
followed by transplantation of hematopoietic cells overex-
pressed some retrovirus-mediated oncogenic proteins (eg
Notch1 and MLL-AF9). Such manipulations destroy the
normal HSC/HPC populations as well as the immune sys-
tem in the recipients; and moreover, they pose a significant
bystander effect on the transplanted cells in the marrow
[6]. Thus the resulted leukemic host will greatly deviate
from the condition of native leukemia development; and
therefore, the traditional models mainly benefit the re-
searches for leukemic cells.
In recent studies, functional alterations of normal
hematopoietic cells in the environment of leukemia
has been highlighted [4, 7–10]. To study “normal”
hematopoietic response to leukemia, the traditional models
would be problematic as discussed above. Hence, the study
should be performed with an un-manipulated leukemia
model in which a normal recipient mouse without any pre-
conditioning is induced to develop leukemia, sustaining a
physiological setting more comparable to that of native
leukemogenesis. To this end, a robust non-irradiated (non-
myeloablated) mouse model for AML has been recently
established, with a 100 % penetrance of leukemia develop-
ment [11]. Thus intact normal blood cells without overt
damage could be directly measured during leukemia pro-
gression. Motivated by the value of this experimental
model, we have digitalized it in the present work; the con-
structed computational model is able to mimic the cell kin-
etics of hematopoiesis under AML. Thus foremost, our
effort may be beneficial for saving experimental costs;
and in turn, potentially facilitating further biomedical
researches. Meanwhile, results attained by the computa-
tional model have reaffirmed the progressive suppression
of hematopoiesis under leukemia, as well as the increased
quiescence of HSCs in leukemic BM.
Results
Workflow
Raw data of cell kinetics were generated by a non-
irradiated AML mouse model, in which normal recipient
mice without any pre-conditioning were induced to de-
velop leukemia at a 100 % penetrance [11]. In the mean-
time, we assembled the knowledge of physics and cell
biology and then conceived a theoretical model (ie the con-
ceptual model). Using the experimental data as reference,
we derived a computational model through parameter
optimization, which was the key step in the procedures of
modeling. Aftermath, we conducted several in silico experi-
ments based on the model mainly by means of parametric
analysis and model selection, and then verified the compu-
tational results with additional experimental references.
Once the model was validated, its predictions (or derivative
deductions) could be regarded as be credible (Fig. 1).
Parameter optimization
Model for the hematopoiesis dynamics of leukemic body
The counts of normal hematopoietic (CD45.1+) and
leukemic (GFP+) cells in peripheral blood (PB), spleen and
BM were monitored and documented from the experimen-
tal mouse model at indicated time points (Additional file 1:
Figures S1A-S1C) [11]. As shown, GFP+ leukemic cells
grew dramatically during leukemia development in all these
tissues. The number of CD45.1+ normal cells in PB had ob-
vious increase after day 7, resulting in the elevation of white
blood cell (WBC) counts at day 14 (Additional file 1: Figure
S1A). Meanwhile, the number of CD45.1+ cells in spleen
slightly increased before day 14, but reduced by day 21
(Additional file 1: Figure S1B). In contrast, the leukemic
BM underwent a modest decrease in cellularity, and the
number of CD45.1+ cells was gradually reduced, reaching a
minimum at day 21 (Additional file 1: Figure S1C). Uitlizing
the experimental data as reference, we established a com-
putational model that was able to mimic the tri-tissue
hematopoietic dynamics under leukemia. The model vari-
ables corresponded to the normal and leukemic cell
counts in the different tissues; and dynamics of the var-
iables depended on the actions of cellular mechanisms (eg
cell proliferation, mobility, death, etc.), which were encoded
by kinetic rate formulas and leukemic influences were con-
sidered. Mathematical forms of the kinetic rates were
adopted from previous studies [12–14], and parameters
were fitted based on the reference data of experimental cell
kinetics. Effective optimization methods were adopted in
the parameter fitting (Methods), and the high fitness illus-
trated that the model parameters (as well as the formulas)
were reasonably estimated (Fig. 2a–c). Therefore, the model
was capable of simulating the cell counts in any/all tissues
at arbitrary time points (ie hematopoietic dynamics) for the
leukemic body.
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Fig. 1 (See legend on next page.)
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Sub-model for the hematopoietic stem/progenitor cell (HSC/
HPC) dynamics in the leukemic environment
Because of the necessity for investigating the hematopoietic
primitive cells (ie HSC/HPC), we also extended the com-
putaitonal model to enclose the HSC/HPC in BM. Al-
though these cells might also reside and grow in other
tissues, BM was undoubtedly the major location for
hematopoietic primitive cells; and the BM HSC/HPC
actually accounted for the large majority of hematopoietic
functions [15]. Again, we utilized the cell counts of HSC
(Lin−c-Kit+Sca1+, LKS+) and HPC (Lin−c-Kit+Sca1−, LKS−),
which amounted to a portion in the BM CD45.1+ popula-
tion (Additional file 1: Figures S1D–S1E), as the reference
data; and the extended model for HSC/HPC dynamics was
established in the similar way as mentioned earlier
(Methods). We estimated the model parameters and a high
(See figure on previous page.)
Fig. 1 Modeling workflow. Adopting the cell kinetics measured from a non-irradiated AML mouse model, the computational model was established
based on physics and biology knowledge via the procedures of parameter optimization (for details, see Methods). Using the model, numerical simulations
could be implemented, eg parametric analysis and model selection. Furthermore, the model was validated with additional experimental results; and once
the model validity was credited, the model could be of certain utilities
Fig. 2 Cell kinetics simulations of the model with the optimized parameters. (a–c). Computational dynamics of the normal and leukemic cells in
PB (a), spleen (b), and BM (c) during leukemia development. These results were generated by the optimized parameters. Exp, Experimental data;
Sim, Simulation results; d1,2, Model fitness degree (d1- leukemic, d2- normal).; s1,2, Sample standard deviation (s1 - leukemic, s2 - normal).
(d–e). Computational dynamics of HSCs (D) and HPCs (E) with the optimized parameters
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fitness was achieved, implying that the parameter
optimization was successful (Fig. 2d–e). As shown in the
cell kinetics, a suppression of hematopoiesis was indicated
during leukemia development as both HSC and HPC in
BM were reduced dramatically.
Model validation
Reproduction for control
A preliminary test for the model validity would be
checking whether the model could correctly reproduce
the normal (ie disease-free) kinetics when the parts
representing leukemic influences in the model were dir-
ectly removed (ie corresponding parameters purged to
zeros without changing anything else), which was sup-
posed to be satisfied by a valid model in the first place.
By simply removing the leukemic-effect terms from the
model while keeping everything else unchanged, we
could see that the normal kinetics, ie, hematopoietic
cells as well as HSCs/HPCs were maintained at nearly
steady levels [11], were reproduced (Additional file 2:
Figure S2). Thus the model not only accurately repre-
sented the leukemia-conditioned hematopoietic dynam-
ics; it could also faithfully reflect the situation under the
normal condition. Therefore, the risk of overfitting for
the leukemia-conditioned dynamics had been lessened;
in other words, the model was likely to have captured
the generic characteristics of hematopoiesis, rather than
artificially-fitted phenomena.
Identifying the major cause of HSC loss in leukemia
The BM HSC (LKS+) level was almost constant under nor-
mal conditions but decreased in leukemia (Fig. 2d and
Additional file 1: Figure S1D). With the advent of the com-
putational model, we could systematically investigate the
relevant factor(s) for the altered HSC kinetics computa-
tionally. Hence, we intended to determine which cellular
mechanism (eg, expansion, differentiation or cell death)
was primarily responsible for the HSC loss during
leukemia development. To this end, parametric analysis
(Methods) was implemented to compute all action rates of
HSCs including cell expansion (fexpn), differentiation (fdiff)
and death (fdeath). The analysis revealed that fexpn and fdiff
were large in both value and variation amplitude, whereas
the value and variation amplitude of fdeath were small
(Fig. 3a). Therefore, the change in HSC level was mainly
due to HSC expansion or differentiation but not cell death.
As fexpn and fdiff are achieved or associated with “prolifera-
tion” via the cell cycle and cell death is mainly induced by
apoptosis, we concluded that the major factor for HSC loss
was an alteration in cell cycle rather than apoptosis. This
analysis could be better visualized in a 3-dimensional form,
displaying fexpn, fdiff, and fdeath on the three dimensions
(Additional file 3: Figure S3A). Noteworthy, the computed
rate for HSC proliferation decreased with time, with rapid
decline occurring around day 10; this suggested that HSCs
became much more quiescent as leukemia cells evolved as
a dominant population (Fig. 3a).
The computational prediction was consistent with the
experimental results of flow cytometry analyses [11]. In
fact, the Annexin V and 7-aminoactinomycin D (7-AAD)
staining, which was for the assessment of apoptosis, re-
vealed that the ratio of Annexin V+ cells in BM HSCs (LKS
+) was nearly unchanged and actually accounted for a small
percentage during leukemia development (Fig. 3b). In con-
trast, the intracellular Ki67 and Hoechst 33342 staining,
which was designed for analyzing the cell cycle of HSCs in
leukemic BM, showed that the cell cycle status of HSCs
changed significantly. Notably, the proportion of HSCs in
the G0 phase (Ki67−, 2 N DNA content) progressively in-
creased during leukemia development, with a large climb
occurring around day 10 (Fig. 3c), which coincided with
the computational result of proliferation rate decline
(Fig. 3a). Interestingly, HSCs in the late stages (after day
14) of leukemia remained in a nearly non-proliferative state
(>92 % LKS+ cells were in G0 in comparison with 40 %
from the control mice, Fig. 3c), as further confirmed by a
BrdU incorporation assay (Additional file 3: Figure S3B).
Taken together, our computational results on the deepened
HSC quiescence were validated by independent cellular as-
says. Therefore, we concluded that the suppression of
HSCs in leukemic BM was mainly due to the functional al-
teration of cell cycle, not apoptosis.
Simulating the hematopoietic differentiation blockade
Given the poor production of blood cells in the late stages
of leukemia development, we further extended our para-
metric analysis to the HPCs. We computed the action
rates of HPCs, namely, HPC generation (ie HSC differen-
tiation into HPC, fHSC->HPC), HPC differentiation (fdiff )
and death (fdeath). The results showed that between the
two factors having both large values and variations, fHSC-
>HPC overrode fdiff at all times and fdiff decayed much faster
than fHSC->HPC, which occurred between days 10 and 12
(Fig. 4a). After day 10, the HPC kinetics was largely dic-
tated by the changes in fHSC->HPC, suggesting that fHSC-
>HPC was the major cause of HPC loss or exhaustion.
Therefore, a blockade of hematopoietic differentiation was
implicated. Meanwhile, fdeath rose moderately around day
12, implying that there might be other cell death-related
events contributing to the loss of HPC.
To further demonstrate and visualize the blockade of
differentiation, we computed the absolute numbers of
HSCs differentiating into HPCs in consecutive time inter-
vals (Methods). Notably, there were indeed fewer and
fewer HSCs differentiating toward HPCs during leukemia
progression, and the number was almost vanished by day
21 (Fig. 4b). This clearly revealed the shutdown of HSC
differentiation, which caused that HPCs could not be
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replenished in leukemic BM. On the other hand, BM
HPCs need to produce mature blood cells; therefore,
BM HPCs suffered a much sharper decline than BM
HSCs and ultimately became exhausted in leukemic
BM (Additional file 1: Figures S1D–S1E).
If the above prediction were true, we should then expect
that the reduction of HSCs/HPCs was correlated with the
hierarchy of differentiation in the hematopoietic cascade.
To this end, data of the whole spectrum of different subsets
of HSC/HPC were adopted [11]. As shown in the data,
three subsets of LKS+ HSCs, namely, LT-HSCs (LKS
+CD34− or LKS+CD150+CD48−), ST-HSCs (LKS+CD34
+Flk2−) and MPPs (LKS+CD34+Flk2+), all suffered pro-
gressive decreases in absolute numbers during leukemia
development (Additional file 4: Figure S4A). Meanwhile,
the absolute numbers of all four subsets of LKS− HPCs in
leukemic BM, namely CMPs (LKS−CD34+CD16/32−),
GMPs (LKS−CD34+CD16/32+), MEPs (LKS−CD34−CD16/
32−), and CLPs (LKlowSlowIL7Rα+), were greatly reduced
during leukemia development (Additional file 4: Figures
S4B-S4C). Obviously, among all of the subsets of primitive
cells, LT-HSCs were the least reduced while the MEPs
Fig. 3 Major factor of HSC loss validated by cell cycle and apoptosis analyses of HSCs in leukemic BM. a Computational decomposition of the
HSC dynamics on the relevant processes. Cell expansion (Expn, red), differentiation (Diff, green) and death (Death, blue). b Flow plots (left panel)
and histogram (right panel) show the apoptosis frequency of HSCs (LKS+) in leukemic BM [11]. c Flow plots (left panel) and histograms (right panel)
show the cell cycle status of HSCs in leukemic BM. Data are represented as the mean ± SEM (n = 12; 3 independent experiments); *p < 0.05 [11]
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were the most reduced at different stages of leukemia
(Fig. 4c, Additional file 4: Figure S4D). In addition, it was
also confirmed that LT-HSC became much more quies-
cent in leukemia (Additional file 4: Figure S4E–S4F).
Therefore, the computational prediction here was con-
firmed; and altogether, these results demonstrated that
leukemic BM resulted in a blockade of hematopoiesis in a
differentiation-dependent manner.
Further computational analyses
Systematicity rather than individuality of modeling
In silico experiments revealed that cell mobility (ie inter-
connections between tissues) was important for modeling
the dynamics of both leukemic and normal cells. In fact,
modeling revealed an improvement of fitness for the ob-
served kinetics in both spleen and BM when cell mobility
was included in the model (ie cell mobility was formulated
as a function of the PB circulation states); whereas the plain
models disregarding cell mobility, ie ignoring it or overlook-
ing its effect as a constant unrelated with PB kinetics, ex-
hibited significantly higher errors (Figs. 5a–d). Hence, the
strategy for modeling individual tissues stipulated in most
of previous studies was unable or insufficient for recon-
structing the complex multi-tissues dynamics in the
leukemic body. In other words, the necessity of studying
the diseased hosts by systematic approaches was reinforced.
Differential cell kinetics in three tissues
By parametric analysis of the model, the rate of each cell ac-
tion was simulated; and we computationally found that the
differences of cell kinetics in the respective tissues were
underlain by the asymmetric leukemic influences on the
cell actions in different tissues. In PB, the cell import rate
(rImport, PB) was larger than (or equal to) the sum of export
Fig. 4 Hematopoietic differentiation blockade validated by reduction folds in different stem and progenitor subsets in the hematopoietic cascade.
a Computational decomposition of the HPC dynamics on relevant processes. HPC generation (ie HSC differentiation into HPC – HSC- > HPC, red), HPC
differentiation (Diff, green) and death (Death, blue). b Absolute numbers of HSCs differentiating towards HPCs in consecutive time intervals simulated
by the computational model. Ti is [day i-1, day i] for i = 1, 2, …, 21. c Reduction folds in different HSC/HPC subsets (upper panel) and an experimental
schema (lower panel) showing the differentiation block from HSCs to HPCs. Numbers −5, −29, etc. indicate the fold decrease [11]
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rate (rExport,PB) and death rate (rDeath,PB) for almost all the
time (Fig. 6a); thus having explained the increase in the PB
CD45.1+ cell number (Fig. 2a and Additional file 1: Figure
S1A). The kinetics of hematopoietic cells in spleen exhib-
ited a short increase at early stage of leukemia (Fig. 2b and
Additional file 1: Figure S1B). In fact, the cell proliferation
rate (rProlif,SP) and death rate (rDeath,SP) were nearly equal;
and the cell import rate (from PB; rImport,PB->SP) was slightly
larger than the cell export rate (rExport,SP->PB) in an early
period of leukemia (Fig. 6b); in addition, rImport,PB->SP de-
creased slower than rExport,SP->PB. Thus the early increase of
spleen cell counts was resulted in. Here we could see that
the pivotal underlying factor is rImport,PB->SP, since although
rProlif,SP is increasing, rDeath,SP almost has the same trend.
Moreover, the facts that “rProlif,SP increased” and “rImport,PB-
>SP > rExport,SP->PB” supported a hypothesis that spleen might
undergo a compensatory mechanism in response to
leukemia. On one hand, it increased cell proliferation; on
the other hand, the cell importation became larger as
hematopoietic cells migrated from elsewhere via PB cir-
culation (due to the malignancy stress, ie destruction of
microenvironments) might be restored in spleen at the
onset of leukemia.
In contrast, the BM cell proliferation rate (rProlif,BM) de-
creased monotonously and the cell export rate (rExport,BM-
>PB) was greater than the import rate (rImport,PB->BM) during
leukemia development (Fig. 6c). The decreased proliferation
could be explained by the suppression of hematopoiesis in
leukemic BM (HSC/HPC losses, Fig. 2d–e and Additional
file 1: Figure S1D-S1E); and the large rExport,BM->PB indicated
that cells migrated out of the BM as the environment be-
came worse during leukemia progression. Notably, at late
stages of leukemia, rExport,BM->PB dropped because BM cells
were depleted as influenced by leukemia, thus fewer normal
cells could escape the malignant environment.
Altogether, the different cell kinetics in the respective
tissues were due to the asymmetric influences that
leukemia exerted on the cell actions; and as shown during
the parametric analyses, the key factors were the cell ex-
port/import rates. Therefore, because the rates of cell ex-
port/import were pivotal in shaping the different cell
kinetics and cell mobility was of great importance to mod-
eling (stated earlier), processes of cell trafficking between
different tissues in the diseased host might also be valu-
able for studying the disease, in addition to the investiga-
tions of leukemic or hematopoietic cells themselves.
Fig. 5 Comparisons of model fitness between systematic and individual modelings. a Inferior fitness of the plain models for the spleen cell
kinetics, which ignore the inter-connections between tissues (cell mobility, CM = 0) or overlooking them as a constant (CM = const) unrelated with
PB kinetics. d1,1, d1,2 - fitness degrees for leukemic kinetics when CM = 0 and const, respectively; d2,1, d2,2 - fitness for normal cell kinetics when CM
= 0 and const. s1,2, Sample standard deviation (s1 - leukemic, s2 - normal). b Box plots illustrate a significantly higher fitness of the model including
the CM as a function of PB kinetics (ie CM = f(L,N), L - PB leukemic cells, N - PB normal cells) for the spleen cell kinetics (one-tail t-test, ** p < 0.005).
c Inferior fitness of the plain models ignoring or overlooking cell mobility for the BM cell kinetics. d Significantly higher fitness of the model
including CM as a function of PB kinetics for the BM cell kinetics (one-tail t-test, *** p < 0.001)
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Possible G0 Re-entry of HSCs for increased quiescence-
implication from model selection
The apparent increase in the percentage of quiescent
HSCs in leukemic BM might involve two possible sce-
narios: (i) cycling HSCs were selectively exhausted or (ii)
more cycling HSCs became quiescent (G0 re-entry).
Since it was difficult to tackle the issue directly by
in vivo experiments, we once again utilized computa-
tional modeling to evaluate which scenario was more
likely (Methods). We found that the model fitness for
the observed HSC cell cycle kinetics was improved when
G0 re-entry was included (Fig. 7a, Additional file 5: Fig-
ures S5A–S5D), whereas the counterpart model without
G0 re-entry exhibited larger errors and failed to repre-
sent the kinetics of quiescent HSCs (Fig. 7b–c). There-
fore, the results showed that scenario (ii) was better
correlated with the experimental data, meaning that a
mechanism causing cycling HSCs to become quiescent
was more likely in response to the leukemic stress.
Although direct experimental validation for the exist-
ence of G0 re-entry was difficult, gene expression profiling
and gene set enrichment analysis (GSEA) revealed that ex-
pressions of quiescence-associated genes were significantly
enriched in the HSCs from leukemic hosts, while expres-
sions of proliferation-associated genes were markedly de-
pleted (Fig. 7d). Futhermore, qRT-PCR confirmed that in
HSCs from leukemic hosts, p19INK4d and p21Cip1 were up-
regulated, and virtually most CDKs and cyclins were sup-
pressed (Fig. 7e) [11]. Therefore, we could conclude that
normal HSCs in leukemic BM were functionally sup-
pressed during leukemogenesis as they were forced to be
in a more quiescent status.
Moreover, the recent work of Miraki-Moud et al. had also
established an equal conclusion that AML did not demolish
Fig. 6 Parametric analyses for differential cell kinetics in PB, spleen and BM. a Action rates of normal cells at the tissue-level (ie total CD45.1+ cells)
in PB during leukemia development. As primitive blood cells rarely occur in PB circulation, the PB cells are regarded as having no proliferation.
b Actions rates of normal cells in spleen during leukemia development. Upper panel: proliferation and death rates for total CD45.1+ cells in spleen; lower
panel: cell export and import rates; red arrow: time point when the number of spleen CD45.1+ cells reaches maximal. c Actions rates of normal
cells in BM during leukemia development. Upper panel: proliferation and death rates for total CD45.1+ cells in BM; lower panel: cell export and
import rates
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normal HSCs but induced arrest or immobilization of cell
cycle by impeding their differentiation [16]. Thus it was ac-
tually equivalent to a further corroboration for our main
conclusions (ie major cause of HSC loss, hematopoietic
blockade, and increased quiescence of HSC under leukemic
stress) in overall.
Discussion
Researches of mathematical modeling for leukemia have
been undertaken for years [13, 14, 17, 18]; while the previ-
ous studies are informative as they have shown the feasibil-
ity of quantitatively and dynamically modeling the cell
kinetics in leukemia, there are also important issues
Fig. 7 Model-selection implication for G0 re-entry of HSCs in leukemic BM. a Failure of the plain model, which is not encoding G0 re-entry, for representing
the kinetics of quiescent HSCs. b Success of the model including the G0 re-entry for representing the kinetics of quiescent HSCs. Here we show one specific
example in which the G0 re-entry is formulated by the most common first-order kinetics, ie linear form. See also Additional file 5: Figure S5 for supplemental
results where the G0 re-entry adopts other forms. c Box plot illustrating that the fitness of the model with G0 re-entry is higher than the
plain model (one-tail t-test, * p < 0.1). See also Additional file 5: Figure S5 for supplemental results in which models with (other forms of)
G0 re-entries uniformly have higher fitness degrees than the plain model. d GSEA for BM HSCs from day 14 leukemia and control mice.
The up-regulation or down-regulation of quiescence-associated gene expressions (left panel) and proliferation-associated gene expressions
(right panel) are shown. The normalized enrichment scores (NES) and p-values are indicated in each plot [11]. e The histograms show cell cycle-related
gene expressions in BM HSCs at leukemia day 14 compared to control. CKIs (left panel), CDKs (middle panel) and cyclins (right panel) were shown. Data
are represented as the mean ± SEM (n = 3, 3 independent experiments), * p < 0.05, ** p < 0.01 [11]
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overlooked that preclude better investigation for the system
of a leukemic body. For instance, the large majority of previ-
ous studies focused on only leukemic cells or single tissues,
whereas few (or none) of them was able to simultaneously
model the hematopoiesis fulfilled by both leukemic and
normal blood cells in multiple tissues of a diseased host.
With the aid of an un-manipulated animal model resem-
bling the physiological condition of leukemogenesis (ie in-
tact normal blood cells without overt damages can be
directly measured during leukemia development), a com-
prehensive computational model that embodies the multi-
tissue dynamics of both leukemic and normal cells in the
leukemic environment, can be established via a systematic
modeling approach. In this study, we proceeded the model-
ing in a hierachically-systematic manner; we first derived a
model on the tissue-level (ie total hematopoietic cells with
respect to the multiple tissues), and then we used the de-
rived model as a basis for building the sub-model of HSCs/
HPCs, with inter-connections of PB with spleen and BM
fully considered. Finally, the HSC sub-model had been
splitted into a even more microscopic scale, in which quies-
cent and active HSCs were distinguished so that HSC quies-
cence could be explored.
Specifically, the key step in the modeling is parameter
optimization. A model will be operational only after all
its parameters are reasonably estimated, which means
that the results produced by the model with the esti-
mates fit the reference data. But rigorously, even a good
model fitness is obtained (with a certain reference data),
the model validity has not come into being, since the
validations must be achieved by additional (independent)
experimental data. Since HSCs/HPCs are of the primary
interests in hematology and experiments with respect to
them are intensive, we therefore run parametric analyses
on them to assess the influential factors for their sup-
pression (or loss) during leukemia development. Actu-
ally, parametric analysis is equivalent to decomposing
the cell kinetics, ie net-effects resulting from actions of
various factors, onto each particular factor. Thus the
major one(s) for the altered hematopoietic kinetics
under leukemia can be found. After performing the ana-
lyses on HSCs/HPCs, ie simulating the action rates asso-
ciated with them, the major cause for HSC loss was
identified (Fig. 3); meanwhile, a hematopoietic differenti-
ation blockade having explained the exhaustion of HPCs
was observed (Fig. 4). Both predictions have been vali-
dated by additional experimental data [11]; and more-
over, another independent work has also supported our
main conclusions [16], thus our computational model
can be credited for validity.
During the modeling, we have had several interesting
findings from the computational viewpoint. First, by work-
ing with the recent data of multiple tissues in leukemic
hosts, we found that the principle of individuality stipulated
in majority of previous modelings no longer worked for a
multi-tissue system. To reconstruct the correct cell kinetics
in different tissues simultaneously, the PB circulation must
be considered and explicitly modeled. For example, if we
neglected it or simply assumed it to be constant term unre-
lated with the PB kinetics, large errors were resulted in. In
contrast, if we considered this term to be a function of the
kinetics of the PB leukemic/normal cells, even with the
simplest form (as described in Methods), the modeling er-
rors were significantly reduced immediately, for the cell
kinetics in both spleen and BM (Fig. 5). Second, parametric
analyses for the cell actions on the tissue-level (ie simula-
tions for the actions of total hematopoietic cells in different
tissues) indicated the reasons underlying the differential
kinetics in PB, spleen, and BM. The computational findings
that the activation of spleen hematopoiesis and increase of
spleen cell influx (at the onset of leukemia), PB cell counts
(WBC) elevation, and the continuous depression of BM
hematopoiesis, suggested the possible response of the host
to leukemia in general (Fig. 6).
Last but not least, we derived a hypothesis via model
selection, which implied that the increased quiescence of
HSCs might be because of re-entry to the G0 phase
under leukemic stress. Nonetheless, it was not unaware
of that the p-value for the model selection was not quite
ideal (Fig. 7a–c); this was because of the scarcity of data.
As shown, there were only five data points to be fitted,
and the first three were just nearly equal since the nor-
mal HSCs still maintained steady levels at early stage of
leukemia (Fig. 7a–b). Therefore, even the false model
could automatically have a fitness of three out of the five
reference data; thus the visual discrimination between
the superior and inferior models were not so impressive.
But obviously, the inferior model could not describe the
kinetic profile of quiescent HSCs in total; thus we could
speculate that if there were more data points existing,
the contrast between the two models would be stronger.
Moreover, on the other hand, the modeling using
only five data points generated the significance level
of p-value < 0.1*; we could well speculate that even if
there were only one more data spot between day10
and day 12 and it had rising trend as that of day 12,
the p-value would be markedly lowered. Hence, al-
though we could not assert the existence of G0 re-entry
based on only the modeling results herein, these results
could still propose a testing method-we could re-perform
the cytometry experiment to measure the HSC counts be-
tween day10 and day 12, and if we found that the number
of quiescent HSCs rose above, the hypothesis of G0 re-
entry would be strengthened. Given the facts that the qui-
escent HSCs are relatively insensible to environmental in-
fluences and also remained highly functional when
transplanted into secondary non-leukemic hosts [4, 11,
16], we believe that acquired quiescence of normal HSCs
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represents a cellular protective mechanism in response to
leukemia. Naturally, more detailed studies for the quies-
cence of HSCs must be subjected to future experiments.
On the other hand, our computational model might be
of valuable utilities. For example, the model as well as
its simulations could be stored in computers (or data-
bases); thus if an animal model of the same diseased
condition is needed, we will not have to build it again or
take the real measurements, we can just refer to the dig-
italized model to retrieve the data for a preliminary as-
sessment or investigation. Therefore, the experimental
costs can be saved. Moreover, such a digitalized model
can also serve as a virtual platform for simulating the ef-
ficacies of drugs or interventions, facilitating the
computer-aided researches for disease therapies.
Conclusion
In this study, we have digitalized an experimental non-
irradiated AML mouse model that is recently estab-
lished. The computational model has been validated with
additional experimental data from multiple aspects; and
given its validity, it may be of potential utilities for future
biology or biomedical researches. Meanwhile, the model-
ing method can also be applied otherwhere. Moreover,
our computational conclusions, altogether with the ex-
perimental supports, provide evidences for the increased
quiescence of BM HSCs and hematopoietic suppression/
blockade under leukemia, which is an attractive perspec-
tive in current hematology. These findings may also pro-
vide insights for more extensive studies, eg therapeutics
of stem cells, or interventions for leukemia.
Methods
Experimental model and data
Data of cell kinetics were adopted from the recently-
established non-irradiated AML mouse model [11]. In this
experiment, counts of normal hematopoietic (CD45.1+)
and leukemic (GFP+) cells in PB, spleen and BM were mea-
sured at day 0, 7, 10, 12, 14 and 21. The sub-populations of
HSCs (CD45.1+LKS+) and HPCs (CD45.1+LKS−) in BM
were also specifically quantified. Specifically, tissue samples
were taken from the (non-irradiated) AML mice at the in-
dicated time points, and flow cytometry was applied to sort
the populations of different cells. Normal and leukemic
cells were sorted by gating on CD45.1+ and GFP+ respect-
ively. HSCs and HPCs were further sorted by gating on the
surface markers Lin- Sca-1+ c-Kit + (LKS+) and Lin- Sca-
1- c-Kit + (LKS-) in the CD45.1+ population, according to
a protocol for broad classification [19, 20]. Frequencies of
different cells in the respective populations, as well as the
absolute cell numbers, were recorded thereby. Besides the
data of cell kinetics, additional data of cell cycle and apop-
tosis analyses of BM HSC, flow cytometry analyses of
HSC/HPC subsets in leukemic BM, and gene expression
analyses, were also provided [11]. These data were utilized
as independent evidences for model validation.
Mathematical modeling
Our model was an analog of a three-compartment sys-
tem containing particles undergoing various processes of
proliferation, decay, transportation, and etc. Specifically,
spleen and BM were two compartments and PB was a
third one that directly connected them; due to PB circu-
lation, the inter-connection between BM and spleen was
via PB. Complying with cell biology, there were at most
four processes influencing cell dynamics within a tissue,
namely, cell proliferation (Prolif ), death (Death), and mi-
grations out of/into the tissue (Export/Import) due to
cell mobility. Meanwhile, noise was reasonably omitted
as the numbers of cell are massive (above 103 ~ 104).
Therefore, the dynamics of cell number (X) in an arbi-
trary population (ie, dX/dt) could generically be a math-
ematical form (Eq. 1):
dX
dt
¼ f Prolif −f Death−f Export þ f Import ð1Þ
where the right-side functions were kinetic rates of the re-
spective cellular actions (ie acting factors of cell dynamics).
Cells in different populations or tissues might undergo
different processes and their actions might follow differ-
ent kinetic laws; moreover, the actions of hematopoietic
cells were also subjected to leukemic influences. For de-
tailed descriptions, refer to Additional file 6.
Numerical optimization for model formulas/parameters
As argued by Almquist et al., although the simultaneous
optimization for both unknown parameters and uncertain
formula structures would be extremely difficult, by finite
enumeration of model structures, the complex model
optimization was reduced to an ordinary issue of param-
eter estimation [21]. Therefore, we assumed that the rates
of cellular actions might follow any of the possible kinetic
forms, eg the zeroth-order kinetics, first-order kinetics, ex-
ponential kinetics, Michaelis-Menten and Hill kinetics, etc.,
which had been studied and adopted in previous researches
to approximate complex biochemical/biological processes
[22–24]. Additionally, the influences of leukemic cells
could adopt the Hill form, as proposed by previous studies
[13, 24]. We successively substituted the specific kinetic
forms into each part of Eq. 1, and thus a pool of dynamical
equations with different formulas was generated. Then, we
selected the best numerical fit(s) in this pool with the aid
of appropriate numerical algorithms of optimization.
The reference data utilized in the parameter optimization
were the cell kinetics measured from the experimental
leukemia model [11]. We used Genetic Algorithm (GA) as
the main approach because it is a heuristic method capable
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of alleviating computational complexity [25]. In addition,
other algorithms (such as the trust-region method) were
also applied as complements, since hybrid usage of them
with GA might enhance the computation efficiency [25].
The criterion was that the mean deviation of the computed
values with respect to the optimized parameters (defined as
the root-mean-square deviation, d) was no larger than the
experimental standard deviation (s), ie, d ≤ s.
Parametric analysis
After completion of the model, we could simulate the
continuous system dynamics with equation-solving ap-
proaches (eg the Gear method). We then utilized the sim-
ulations to calculate the cell action rates (right side of
Eq. 1), which amounted to projecting the cell dynamics
(left side of Eq. 1) on different acting factors correspond-
ing to cellular mechanisms or bio-processes. In fact, for a
dynamic process depicted by Eq. 1, the projection of the
variation rates of cell numbers (at arbitrary time t) on a
single acting factor directly indicated how much this term
caused the cell number to change (at time t). In this man-
ner, contributions of different factors could be assessed
and the major one(s) could be found. Generically, given
the simulation results of hematopoietic and leukemic cell
dynamics {X(tj) : j = 0,1, …} and {L(tj) : j = 0,1, …}, the spe-
cific rate (at arbitrary tj) of any cellular action for
hematopoietic cells could be calculated as:
f i X tj
 
;K L tj
   
; i∈ Prolif ;Death; Import;Export;Expn;Difff g
ð2Þ
where fi were the kinetic forms and K was a function en-
coding leukemic influences as mentioned earlier.
Model selection
Using the model framework as the working platform, we
could in silico evaluate different (usually opposite) sce-
narios; eg, the necessity of cell mobility, and the possibil-
ity of G0 re-entry. Generally, different equations could
be formulated according to whether a hypothesis or its
null counterpart was adopted. Thus two models distinct
from each other were formed, eg with or without cell mo-
bility/G0 re-entry. Statistical tests were then performed to
examine which model possessed superior fitness for the
(given) reference data; and the selected model was as-
sumed to be more likely to have produced the experimen-
tal data. In the present work, the one-tail t-test was used
to check whether the mean error resulted by one model
was significantly lower (or higher) than that of the other
in the fitting of reference data. For more details, refer to
Additional file 6.
Additional files
Additional file 1: Figure S1. Raw data of cell kinetics from experiment.
(A–C). Absolute numbers of CD45.1+ normal hematopoietic cells and GFP+
leukemia cells in PB (A), spleen (B) and BM (C) during leukemia development
(n = 5-7). Ctrl, Control mice [11]. (D–E). Absolute numbers of CD45.1+LKS+ (D)
and CD45.1+LKS− (E) cells in leukemic BM (n= 4-5) [11]. (PNG 71 kb)
Additional file 2: Figure S2. Reproduction of the normal control by
the model. (A–C). Computational and experimental cell kinetics of PB (A),
spleen (B) and BM (C) under the normal condition. The computation
results are yielded by directly eliminating the parameters for leukemic
effects in the mathematical model. Experimental data are taken from Ref
[11]. (D). Computational and experimental kinetics of BM HSCs/HPCs under
the normal condition. (E). Computational and experimental kinetics of
quiescent and active HSCs in BM under the normal condition. (PNG 79 kb)
Additional file 3: Figure S3. Supplemental data for illustrating the
major factor of HSC loss. (A). The 3D visualization of projections of the
HSC dynamics. Expn, Diff and Death are the orthogonal axes; and the
rates projected on them are bars with lengths proportional to the values.
Prolif is symbolized as the vectorized composition of Diff and Expn.
Temporal profiles at day 0, 7, 10, 12, 14 and 21 are given. (B). Flow plots
(left panel) and histogram (right panel) show the BrdU incorporation of
HSCs (LKS+ cells) in leukemic BM. Data are represented as the mean ±
SEM (n = 8, 2 independent experiments). *** p < 0.001 [11]. (PNG 165 kb)
Additional file 4: Figure S4. Supplemental data for illustrating the
differentiation blockade in the hematopoietic cascade. (A). Absolute
numbers of LT-HSCs, ST-HSCs and MPPs in leukemic BM [11]. (B–C).
Absolute numbers of CMPs, GMPs, MEPs (B) and CLPs (C) in leukemic
BM. Data are represented as the mean ± SEM (n = 12, 3 independent
experiments). * p < 0.05, ** p < 0.01, *** p < 0.001. + or -, increase or decrease
[11]. (D). A pattern showing linear correlation between the reduction
and differentiation hierarchy in the hematopoietic cascade. The reduction of
LT-HSC was normalized to −1, and the bars indicate normalized reduction
level [11]. (E). Flow plots (left panel) and histograms (right panel) show the
cell cycle status of LT-HSCs in leukemic BM. Data are represented as the
mean ± SEM (n = 12, 3 independent experiments). * p < 0.05 [11]. (F). Flow
plots (left panel) and histogram (right panel) show the BrdU incorporation
of LT-HSCs in leukemic BM. Data are represented as the mean ± SEM (n = 8,
2 independent experiments). *** p < 0.001 [11]. (PNG 135 kb)
Additional file 5: Figure S5. Supplemental data for illustrating the
increased quiescence of HSCs. (A-B). Fitness of the models including the
G0 re-entry, which adopts two other forms: the Hill form (A) and exponential
form (B). Reference data for the kinetics of quiescent HSCs were taken from
the cell cycle analyses (Fig. 3c) [11], in which percentage numbers (G0) were
transformed into absolute numbers by multiplying the total cell count of
HSC population (CD45.1+LKS+, Additional file 1: Figure S1D). (C–D). Box plots
show that the mean errors of the models with G0 re-entry are uniformly
lower than the plain model (one-tail t-test, * p < 0.1). (PNG 54 kb)
Additional file 6: Descriptions in-detail for the computational model.
Descriptions of the modeling process and computational procedures are
enclosed; concrete mathematical formulas and (optimized) parameter
values are also provided. (DOCX 152 kb)
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